Speciality Chemicals Sector: Is India Really Capturing the China Plus One Opportunity?

Status as of July 2026

Company results and analyst ratings below reflect Q3 FY26 results, reported January to February 2026, and Budget 2026 to 2027 announcements from February 2026. US tariff policy, Chinese export pricing and individual company guidance can all change quickly. Check current quarterly results and analyst notes before relying on any specific figure or rating here.

For years, China Plus One, often shortened to China+1, has been the single most repeated phrase in any bullish pitch for Indian speciality chemical stocks. The story is clean: global manufacturers, uneasy about how concentrated their supply chains are in China, diversify sourcing toward India, and the sector grows structurally as a result, independent of any single product cycle. The last eighteen months of actual company results tell a considerably messier story than that clean version.

The sector had a genuinely tepid first half of FY26, hurt in part by the very same geopolitics the China Plus One thesis is supposed to benefit from, since a wave of US tariffs landed on some of India's own chemical exports at the same time China's own producers were dumping excess bulk capacity into export markets.

Against that backdrop, a handful of companies still posted real, substantial acceleration in the same stretch. Sorting out where the thesis is genuinely showing up in the numbers, and where it remains mostly a narrative, matters more than reaching for a single verdict on the sector as a whole.

India's speciality chemicals market was valued at roughly USD 63 billion in 2024, with industry estimates projecting growth toward USD 95 billion by 2030, and the China Plus One narrative is cited across nearly every research note on the sector as a structural driver behind that growth.

The trouble with the simple version of this story is that it treats speciality chemicals as one undifferentiated basket, when the sector actually spans everything from highly proprietary, patent protected molecules sold to a handful of global pharmaceutical innovators, to genuinely commoditised bulk chemicals that compete on price against Chinese capacity every single day. China Plus One does not move through those two ends of the business at the same speed, or sometimes in the same direction at all.

The scale India is up against is worth stating plainly. China still produces an estimated 70% of the world's active pharmaceutical ingredients and roughly half of global agrochemical intermediates. Global pharmaceutical and agrochemical companies are reported to be awarding somewhere in the range of 20% to 30% of their annual order flow to Indian manufacturers as part of a deliberate diversification strategy, a meaningful shift in direction but still a minority share of the total pie China continues to hold.

India capturing a growing slice of new order flow is a genuinely different, and much more modest, claim than India displacing China as the world's primary chemical supplier.

Rather than a smooth upward trajectory, the sector's first half of FY26 was widely described by brokerages as tepid and subdued. Excessive rainfall across key Indian states hurt domestic agrochemical application and demand, a purely domestic, weather driven headwind unrelated to China Plus One.

Export demand softened after a period of pre tariff buying pulled orders forward into the first quarter, leaving a weaker second quarter behind it. Global peers including Dow Chemical and Eastman Chemical also downgraded their own guidance over the same period, citing soft demand in consumer durables and construction, a reminder that some of the sector's weakness reflected a broader global chemicals downturn rather than anything specific to India's competitive position against China.

The sharpest complication came from an unexpected direction. A wave of US tariffs landed directly on specific Indian chemical exports, including refrigerant gases such as R32 and R125, methyl methacrylate, and the herbicide 2,4 D, affecting SRF, Navin Fluorine, Gujarat Fluorochemicals, Aarti Industries and Atul among others.

The same geopolitical environment that is supposed to push global buyers away from China and toward India also produced tariff barriers on India's own exports to one of its largest markets, at least temporarily offsetting part of the structural tailwind the China Plus One story is built around.

Aarti Industries specifically cited a resumption of paused exports to the US as a driver of improved results in the following quarter, confirming the disruption had been real rather than merely a risk analysts were pricing in preemptively.

The clearest evidence for China Plus One actually delivering shows up in businesses built around proprietary process chemistry and long term contractual relationships, rather than commodity price competition.

Navin Fluorine posted a nearly 26% year on year revenue increase and net profit up more than 189% year on year in the December quarter, driven by new fluorination capacity and a contract manufacturing relationship with Honeywell, a named global counterparty rather than a generic export statistic.

PI Industries operates a custom synthesis and manufacturing model in which global innovator companies fund process chemistry development themselves and then award exclusive supply contracts running five to seven years, a structure that is difficult for a Chinese competitor to displace once in place, regardless of price.

Vinati Organics holds an estimated 65% global market share in two specialty monomers, isobutyl benzene and ATBS, a case of an Indian producer holding outright global leadership in specific molecules rather than merely benefiting from diversification away from China.

At the more commoditised end of the business, the picture looks considerably less favourable. Brokerages have explicitly flagged Chinese dumping as a drag on bulk chemical players through this period, with Chinese producers pushing excess capacity into export markets at aggressive prices once they lose share in higher value categories, directly undercutting Indian producers competing on the same commodity products.

This is the segment where the simple China Plus One story is weakest: a molecule with limited differentiation and multiple willing suppliers remains a price competition, and China's scale and lower cost base still generally wins that competition when it chooses to compete on price.

Segment	How China Plus One Is Playing Out
Custom synthesis and CDMO, long term contracts	Genuine structural wins; high switching costs favour incumbents like PI Industries and Navin Fluorine
Proprietary, globally dominant molecules	Clear India leadership in specific cases, such as Vinati Organics in specialty monomers
Bulk and commodity chemicals	Still exposed to Chinese dumping and price competition; weaker evidence of durable share gains
Export orientated segments hit by US tariffs	Temporarily disrupted in 2025, with signs of recovery as exports resumed

Perhaps the clearest evidence that this is not a single, uniform sector story is how differentiated analyst ratings on individual names actually are, often within the very same research note citing the China Plus One theme.

One widely cited brokerage note carried Buy ratings on Atul, Aarti Industries, Epigral, GHCL and Vishnu Chemicals, an Add rating on SRF and Anuras, but a Reduce rating on PI Industries, Navin Fluorine and Deepak Nitrite, and a Sell rating on Gujarat Fluorochemicals, all in the same sector, under the same broad narrative.

That spread reflects genuine differences in valuation, near term earnings visibility and exposure to the commodity end of the business, not a uniform view that speciality chemicals as a category is either a buy or a sell right now.

Rating	Companies
Buy	Atul, Aarti Industries, Epigral, GHCL, Vishnu Chemicals
Add	SRF, Anuras
Reduce	PI Industries, Navin Fluorine, Deepak Nitrite
Sell	Gujarat Fluorochemicals

Ratings from a single brokerage note cited in sector coverage around Q2 FY26 results, included to illustrate the spread of views within one research house rather than as a current recommendation. Ratings change frequently; check a broker's latest note for current views.

China Plus One was never a promise that India would out compete China everywhere at once. It was always going to show up first in the chemistry China cannot easily replicate, and slowest in the chemistry it can.

What This Means for an Investor

A few practical conclusions follow from how unevenly this thesis has actually played out:

• Do not treat speciality chemicals as a single trade on a single narrative. The same theme is producing genuinely different outcomes at the proprietary, relationship driven end of the business than at the commoditised, price competitive end.

• Check whether a specific company's China Plus One exposure comes through long term contracts and proprietary chemistry, which are harder for China to compete away, or through generic export volume in commodity products, which remains vulnerable to Chinese dumping.

• Separate temporary disruptions, such as the 2025 US tariff impact on specific exports, from the underlying structural thesis, since the two can move in opposite directions in the same period without either one disproving the other.

• Read the specific analyst rating on an individual name rather than assuming a bullish sector theme applies uniformly, given how differentiated ratings across the sector's own largest names actually are.

• Track quarterly results for concrete evidence, such as new named customer contracts or capacity commissioning, rather than relying on the China Plus One narrative alone as a reason to hold or buy a specific stock.

The same brokerage note that pointed to a China Plus One driven recovery also carried a Sell rating on one of the sector's best known fluorochemical names. Both were true at once.

This article is for educational purposes only and does not constitute investment advice. Company results, market size estimates and analyst ratings cited are drawn from published brokerage research and news coverage as publicly available at the time of writing and are subject to change. Past performance is not indicative of future results. Readers should consult a SEBI registered investment adviser before making investment decisions.